Policy on Human Papilloma Virus Vaccinations

3 Originating Council

- 4 Council on Clinical Affairs
- 5 Adopted
- 6 2017

7

2

- 8 Purpose
- 9 The American Academy of Pediatric Dentistry recognizes there is a link between Human Papilloma Virus
- and development of oral pharyngeal cancers. The purpose of this policy is to provide a perspective on
- dental provider's role in discussing oral cancers and connections to Human Papilloma Virus (HPV).

12

- 13 Methods
- 14 This policy is a review of current dental and medical literature. An electronic search was conducted using
- the PubMed® electronic database with the following parameters: Terms: "HPV vaccines", and "HPV and
- oral cancer" "HPV and cancer" "Guardisil and prevention of cancer" Fields: all; Limits: within the last 10
- 17 years, humans, English, birth through age 99. Eighteen articles matched these criteria. Papers for review
- were chosen from this list and from the references within selected articles.

19

- 20 Background
- 21 Human Papillomavirus (HPV) is associated with anogenital, skin, oral and oropharyngeal cancers
- 22 (OOPC)<sup>1, 2</sup>. The same virus is observed in oral squamous cell carcinoma, the most common type of oral
- OOPC<sup>2</sup>. Based on current epidemiological trends, 44,330 new cases and 9,350 deaths due to OOPC are
- expected to occur in 2016<sup>5</sup>. HPV is a critical factor with the HPV 16 strain being the most prevalent<sup>6</sup>. The
- 25 association between HPV infection and OOPC may be responsible for the recent change epidemiology
- with the disease affecting younger population groups.

27

- HPV infection is preventable through immunizations and vaccines have been available since 2006<sup>7</sup>. The
- 29 Center for Disease Control (CDC) found that the prevalence of HPV infection decreased 56% among
- female teenagers since the vaccine was introduced<sup>8</sup>. HPV vaccine efficacy against anal and oral infection
- 31 is high and similar to that against cervical infection. Because the same virus strains are strongly
- associated with OOPC, it is reasonable to assume that HPV vaccines play an important role in oral

pharyngeal cancer prevention. Although there are no studies showing that the HPV vaccine prevents the 33 34 development of OOPC, it is reasonable to postulate the vaccine's potential since the vaccine has been shown to prevent HPV infection<sup>3</sup>. Despite the increased availability of the HPV vaccines, HPV-related 35 OOPC incidence has continued to increase significantly. 36 37 38 The American Academy of Pediatrics recommends HPV vaccination for all 11-12 year old children and 39 include females up to age 26 and males up to age 21 that have not been previously vaccinated. The vaccinations can be administered as early as 9 years of age<sup>10</sup>. Initially the AAP recommended a series of 3 40 41 vaccines over a six month period, with the second dose occurring 1-2 months following the first with the 42 third dose 6 months following, 11 Low compliance rates for completion of the vaccination series are due to access, willingness of physicians to discuss with parents, and cost. 12-15 Recently the CDC Advisory 43 44 Committee on Immunization Practices (ACIP) recommended a two-dose schedule for children vounger 45 than 15 years of age with both doses 6-12 months apart. For children older than 15 years, the three-dose 46 schedule is still recommended.<sup>16</sup> 47 Adolescent patients have unique needs related to oral health care. Pediatric dentists typically provide 48 tobacco and nutritional counseling to their adolescent patients.<sup>17</sup> Given that dental professionals are 49 50 already involved in secondary and tertiary prevention and to a limited extent in the treatment of OOPC, offering primary prevention in dental clinics seems a logical and clinically appropriate approach. As 51 52 adolescent patients tend to see the dentist twice yearly and more often than their medical doctor this is a 53 window of opportunity for the dental professional to provide counseling to the patient and parent about

54 55

56

## Policy Statement

The AAPD supports measures that prevent OOPC, including the prevention of HPV infection, a critical factor in the development of oral squamous cell carcinoma.

59

60

61

62 63

64

65

The AAPD encourages oral health care providers to:

the HPV vaccine and HPV's link to oral cancer. 18

- Educate patients, parents, and guardians on the serious health consequences of OOPC and the relationship of HPV to OOPC.
- Counsel patients, parents, and guardians regarding the HPV vaccination, in accordance with CDC recommendations, as part of anticipatory guidance for adolescent patients (ages 10-18<sup>17</sup>).
- Routinely examine patients for oral signs of and changes consistent with OOPC.

• Follow current literature and consider incorporating other approaches for HPV prevention in their practices so as to minimize the risk of disease transmission.

68

69

## References

- 70 1. Chattopadhyay, A., Weatherspoon, D. & Pinto, A. Human Papillomavirus and Oral Cancer: A
- Primer for Dental Public Health Professionals. Community Dental Health. 2015; 32: 117-128.
- 72 2. Daley, E., DeBate, R., Dodd, V., Dyer, K., Fuhrmann, H., Helmy, H., & Smith, S. A. (2011).
- Exploring awareness, attitudes, and perceived role among oral health providers regarding HPV-
- related oral cancers. J Public Health Dent. 2011; 71(2): 136-142.
- 75 5. American Cancer Society. (2016). Cancer Facts and Figures 2016.
- 76 6. Weatherspoon, D. C. Oral cavity and oropharyngeal cancer incidence trends and disparities in the
- 77 United States: 2000–2010. Cancer Epidemiology.2015
- 78 7. Dunne, F. M. (2015). CDC Grand Rounds: Reducing the Burden of HPV Associated Cancer and
- 79 Disease. CDC.
- 80 8. Markowitz, L. E., Hariri, S., Lin, C., Dunne E. F., Steinau, M., McQuillan, G., & Unger, E. R.
- Reduction in human papillomavirus (HPV) prevalence among young women following HPV
- vaccine introduction in the United States, National Health and Nutrition Examination Surveys,
- 83 2003-2010. J Infect Dis 2013; 208(3): 385-93.
- 84 9. Beachler, C. K. Multisite HPV 16/18 Vaccine Efficacy Against Cervical, Anal and Oral HPV
- 85 Infection. Journal of National Cancer Institute, 108, 2015
- 86 10. Centers for Disease Control and Prevention. MMWR. (2015). Use of 9-Valent human
- papillomavirus (HPV) vaccine: updated HPV vaccination recommendation of the advisory
- 88 committee on immunization practices.
- 89 11. American Academy of Pediatrics. Policy statement HPV vaccine recommendations. Pediatrics
- 90 2012, 129 (3) 602-605.
- 91 12. McRee AG. HPV vaccine hesitancy: Findings from a statewide survey of health care providers. J
- 92 Pediatr Health Care. 2014; 28(6): 541-9.
- 93 13. Siddiqui M, Salmon DA, Omer SB. Epidemiology of vaccine hesitancy in the United States. Hum
- 94 Vaccin Immunother 2013; 9(12): 2643-8.
- 95 14. Henrikson NB, Opel DJ, Grothaus L, Nelson J, Scrol A, Dunn J, et al. Physician communication
- training and parental vaccine hesitancy: A Randomized trial. Pediatrics 2015; 136(1): 70-9.
- 97 15. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. National
- human papillomavirus vaccination coverage among adolescents aged 13-17 years—National

Immunization Survey—Teen, United States, 2011. MMWR 2014; 63(02):61-60. 99 Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus 100 Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices 101 MMWR. 2016;65(49);1405-8. Available at: 102 103 "https://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm". Accessed March 22, 2017. (Archived by WebCite® at "http://www.webcitation.org/6p9sQn2nr"). 104 American Academy of Pediatric Dentistry. Adolescent Oral Health Care. Pediatric Dentistry. 105 17. 106 2016; 38(6):155-63. 107 18. Irwin, C. E., Jr., Adams, S. H., Park, M. J., & Newacheck, P. W. Preventive care for adolescents: 108 few get visits and fewer get services. Pediatrics. 2009; 123(4): e565-572. doi:10.1542/peds.2008-109 2601